Obesity Drug Pipeline 2026: What It Means for CROs, CDMOs and Biotechs
Updated: 6 days ago
Key Takeaways
GLP-1 therapies now come as pills, not just injections. The Wegovy pill (oral semaglutide 25 mg) was approved in the US in December 2025 and in the EU in July 2026. Orforglipron, the first small-molecule GLP-1 agonist for obesity, was approved by the FDA in April 2026 (FDA, 2026).
The efficacy bar keeps rising. Retatrutide, a GIP / GLP-1 / glucagon triple agonist, reported 28.3% mean weight loss at 80 weeks in Phase 3 (Eli Lilly, 2026), compared with 14.9% for semaglutide 2.4 mg and 20.9% for tirzepatide in their pivotal trials.
The pipeline now spans four receptor families. GLP-1, GIP, glucagon and amylin are all targeted, through amylin-based drugs (CagriSema, amycretin, eloralintide), glucagon co-agonists (survodutide, mazdutide), monthly dosing (MariTide) and new dual agonists such as Viking's VK2735, developed as both an injection and a pill.
China is now an obesity innovation hub. Mazdutide and ecnoglutide are already approved there, and Chinese developers increasingly look for US and EU development partners.
The next differentiators go beyond weight loss. Lean mass preservation, durability after stopping, patient experience on treatment and long-acting formats are becoming as important as the headline number.
Ten years ago, obesity drugs delivered single-digit weight loss.
In 2026, a Phase 3 trial reported close to 30%, two GLP-1 pills reached the US market, and China approved its own new molecules.
The obesity drug pipeline has become one of the most active in pharma. This article gives a factual overview of what is approved in the US and EU, what is coming next worldwide, and how each class of molecule works.
It then looks at what this wave means for the CROs, CDMOs and biotechs that support drug development.
On the market in the US and EU
Six GLP-1-based options are now approved in the US, the EU or both. 2026 marked the arrival of daily pills next to weekly injections.
Molecule (brand) | Company | Mechanism and route | Status | Headline result |
|---|---|---|---|---|
Tirzepatide (Mounjaro, Zepbound) | Eli Lilly | GIP / GLP-1 agonist, weekly injection | US, EU | 20.9% at 72 weeks (SURMOUNT-1) |
Semaglutide 7.2 mg (Wegovy) | Novo Nordisk | GLP-1 agonist, weekly injection | EU (Feb 2026) | 20.7% at 72 weeks (STEP UP) |
Oral semaglutide 25 mg (Wegovy pill) | Novo Nordisk | GLP-1 agonist, daily pill | US (Dec 2025), EU (Jul 2026) | 16.6% at 64 weeks (OASIS 4) |
Semaglutide 2.4 mg (Wegovy) | Novo Nordisk | GLP-1 agonist, weekly injection | US, EU | 14.9% at 68 weeks (STEP 1) |
Orforglipron (Foundayo) | Eli Lilly | Small-molecule GLP-1 agonist, daily pill | US (Apr 2026), UK (Aug 2026), EU under review | 12.4% at 72 weeks (ATTAIN-1) |
Liraglutide 3.0 mg (Saxenda) | Novo Nordisk, generics | GLP-1 agonist, daily injection | US, EU | 8.0% at 56 weeks (SCALE) |
Orforglipron deserves a note. It is the first non-peptide GLP-1 agonist approved for obesity, and it can be taken without food or water restrictions, unlike oral semaglutide.
Older options remain available, such as orlistat and naltrexone/bupropion, along with setmelanotide, an MC4R agonist for rare genetic forms of obesity.
The next wave in the obesity drug pipeline
The pipeline is moving beyond GLP-1 alone, toward amylin, glucagon, triple agonism, monthly dosing and new oral options, with China emerging as a hub of its own.
Molecule (brand) | Company | Mechanism | Status | Headline result |
|---|---|---|---|---|
Retatrutide | Eli Lilly | GIP / GLP-1 / glucagon triple agonist | Phase 3 | 28.3% at 80 weeks (TRIUMPH-1) |
Amycretin | Novo Nordisk | Unimolecular GLP-1 / amylin agonist | Phase 3 | 24.3% at 36 weeks (Phase 1b/2a) |
CagriSema | Novo Nordisk | Amylin analogue + GLP-1 agonist | Filed with FDA, decision expected Q4 2026 | 22.7% at 68 weeks (REDEFINE 1) |
Eloralintide | Eli Lilly | Selective amylin agonist | Phase 3 | Up to 20% at 48 weeks (Phase 2) |
MariTide | Amgen | GLP-1 agonist + GIP antagonist, monthly | Phase 3 (MARITIME) | About 20% at 52 weeks (Phase 2) |
Mazdutide (Xinermei) | Innovent Biologics | GLP-1 / glucagon dual agonist | Approved in China | 18.6% at 60 weeks (GLORY-2) |
Survodutide | Boehringer Ingelheim, with Zealand Pharma | GLP-1 / glucagon dual agonist | Phase 3 completed | 16.6% at 76 weeks (SYNCHRONIZE-1) |
VK2735 | Viking Therapeutics | GIP / GLP-1 dual agonist, injection and pill | Phase 3 (VANQUISH), oral Phase 3 planned | Up to 14.7% at 13 weeks (Phase 2, injection) |
Ecnoglutide (Xianweiying) | Sciwind Biosciences, Pfizer in China | cAMP-biased GLP-1 agonist | Approved in China (Mar 2026) | 15.1% placebo-adjusted (Phase 3) |
VK2735 is one to watch. Its injectable form is in two fully enrolled 78-week Phase 3 trials (VANQUISH-1 and VANQUISH-2), and its oral form reached up to 12% weight loss at 13 weeks in Phase 2. If successful, it could become the first oral dual GLP-1 / GIP agonist on the market.
Further upstream, programs target new biology:
siRNAs against INHBE or ALK7
Activin and myostatin blockade to preserve lean mass
Peripherally restricted CB1 blockers
Once-monthly prodrugs and long-acting depot technologies aiming at dosing every 3 to 6 months
How these molecules work: from one receptor to four
All of these drugs mimic or modulate gut and pancreatic hormones that regulate appetite, satiety and energy use.
Class | Example molecules | Mechanism |
|---|---|---|
GLP-1 receptor agonist | Semaglutide, liraglutide, orforglipron, ecnoglutide | Increases satiety through the hypothalamus and hindbrain, slows gastric emptying and stimulates glucose-dependent insulin release. |
GIP / GLP-1 dual agonist | Tirzepatide, VK2735 | Adds GIP receptor agonism, which acts on adipose tissue and central appetite circuits. |
GLP-1 / glucagon dual agonist | Survodutide, mazdutide | The glucagon component increases energy expenditure and hepatic fat oxidation, which also makes these molecules relevant in liver disease. |
Triple agonist | Retatrutide | Combines GIP, GLP-1 and glucagon receptor agonism in a single molecule. |
Amylin-based | CagriSema, amycretin, eloralintide | Mimics amylin, a hormone co-secreted with insulin, which signals satiety through the area postrema. Used alone or with GLP-1. |
GLP-1 agonist + GIP antagonist | MariTide | An antibody-peptide conjugate whose long half-life allows monthly dosing. |
Across the landscape, four receptor families are now targeted: GLP-1, GIP, glucagon and amylin receptors. A single molecule engages up to three of them today, with retatrutide. Future approaches will likely combine more of these pathways.
Targeting does not always mean activating. Both GIP agonism (tirzepatide) and GIP antagonism (MariTide) are associated with weight loss when combined with GLP-1, and the underlying biology is still being clarified.
Beyond percent weight loss
As headline numbers converge near 20% and above, the field is shifting from how much weight is lost to the clinical value and quality of that loss.
Hard outcomes and new indications
SELECT showed a 20% reduction in major cardiovascular events with semaglutide, and SURMOUNT-MMO is testing tirzepatide on morbidity and mortality.
Indications are expanding into sleep apnea, MASH, heart failure and kidney disease.
Quality of weight loss
Part of the weight lost on incretin therapies is lean mass. Activin and myostatin pathway programs aim to preserve muscle while fat is lost.
Maintenance after stopping
In the STEP 1 extension, participants regained about two thirds of the weight they had lost within a year of stopping semaglutide, and SURMOUNT-4 showed a similar pattern with tirzepatide.
Sponsors are now studying withdrawal, dose reduction, switches from injectables to oral therapy, and less frequent maintenance regimens. Viking, for example, is testing monthly and every-other-week dosing of VK2735 for long-term weight management.
Patient experience on treatment
Patient-reported outcomes in current labels mostly measure what weight loss gives back, such as physical function or knee pain. They capture much less of what treatment feels like day to day: GI burden, fatigue, food noise, mood or mental clarity.
That experience likely drives one of the field's biggest real-world issues, persistence on therapy. Validated clinical outcome assessments (COAs) on life during treatment could become a real differentiator.
Safety in context
GI side effects are common, especially during dose escalation. Rare risks are also documented: in 2025, the EMA concluded that NAION (non-arteritic anterior ischemic optic neuropathy) is a very rare side effect of semaglutide, affecting up to 1 in 10,000 people, and patients with pre-existing diabetic retinopathy need eye monitoring.
As with any medicine, benefits and risks should be weighed with a physician, based on peer-reviewed data.
Care models
For many patients, these therapies have become a front door to the healthcare system: regular visits and lab work surface comorbidities that were previously unmanaged. How sponsors, payers and providers turn that engagement into long-term outcomes is an open question.
What this means for CROs, CDMOs and biotechs
The obesity wave creates demand well beyond the large sponsors, and the service providers that position early stand to benefit most.
For CROs
Many large Phase 3 obesity trials now run in parallel, which makes patient recruitment and site capacity highly competitive. Outcomes trials are long and large, and new indications (MASH, sleep apnea, heart failure, kidney disease) call for specialized expertise.
Body composition imaging, cardiometabolic biomarkers, patient-reported outcomes and long-term follow-up for maintenance studies are growing needs. For CROs that want to capture this demand, a predictable sales pipeline matters as much as therapeutic expertise.
For CDMOs
Peptide manufacturing capacity remains in high demand as injectables scale, one of the drivers behind CDMO market growth in 2026.
The arrival of oral small molecules such as orforglipron shifts part of the need toward conventional solid dose manufacturing, with no cold chain. Combination products, monthly formulations and long-acting depots add complexity in formulation, fill-finish and device work, and sponsors weigh these capabilities closely when they select a CDMO.
For biotechs
The emerging mechanisms (amylin, muscle preservation, siRNA, long-acting formats) create partnering windows, as large companies look to complete their portfolios. Differentiation is moving toward tolerability, dosing frequency, quality of weight loss and durability.
Service providers targeting these companies can draw on our guide on how to sell to biotech startups.
China as a reference point
With mazdutide and ecnoglutide approved and more programs advancing, China is now both a source of innovation and a partnering market. Chinese companies increasingly look for US and EU development partners, a trend that intersects with the BIOSECURE Act reshoring debate.
Frequently asked questions
What are the newest obesity drugs approved in 2026?
In the US, orforglipron (Foundayo), the first oral small-molecule GLP-1 agonist for obesity, was approved in April 2026, after the Wegovy pill in December 2025. In the EU, the Wegovy pill and semaglutide 7.2 mg were approved in 2026. In China, ecnoglutide was approved in March 2026.
What is the difference between GLP-1 and amylin-based obesity drugs?
GLP-1 agonists act on GLP-1 receptors in the brain and gut to increase satiety and slow gastric emptying. Amylin-based drugs mimic amylin, a pancreatic hormone that signals fullness through a different brain region. They can be used alone, as with eloralintide, or combined with GLP-1, as with CagriSema and amycretin.
Which receptors do new obesity drugs target?
Four receptor families are now targeted across the obesity pipeline: GLP-1, GIP, glucagon and amylin receptors. A single molecule engages up to three of them today, as with retatrutide. Targeting does not always mean activation: MariTide combines GLP-1 agonism with GIP receptor antagonism.
Which obesity drug showed the highest weight loss in a Phase 3 trial?
As of September 2026, retatrutide, a GIP / GLP-1 / glucagon triple agonist from Eli Lilly, reported the highest mean weight loss in a Phase 3 obesity trial: 28.3% at 80 weeks in TRIUMPH-1 (12 mg).
Are there oral obesity drugs?
Yes. Oral semaglutide 25 mg (Wegovy pill) is approved in the US and EU, and orforglipron (Foundayo) is approved in the US and UK, with an EU review ongoing. Oral versions of amycretin and of Viking Therapeutics' VK2735 are also in development.
Looking ahead
The obesity field is moving from one receptor to four, from injections to pills and monthly doses, and from weight loss alone to long-term outcomes and patient experience.
For service providers, that means new trial designs, new manufacturing needs and new partners to reach.
At Corstrate, we help small life sciences service providers (CROs, CDMOs and biotechs) identify and engage the right sponsors in the US and EU. If obesity and cardiometabolic programs are part of your growth strategy, we would be glad to talk.
Methodology note: headline figures are mean percent changes in body weight as reported in publications or company disclosures. Trials differ in population, duration, dose and estimand (for example, whether results assume all patients stayed on treatment), so figures are not head-to-head comparisons. Regulatory status as of September 2026, article updated October 2026.
Sources
Tirzepatide: SURMOUNT-1, NEJM 2022; SURMOUNT-4, JAMA 2024
Semaglutide 2.4 mg: STEP 1, NEJM 2021, and its extension; SELECT, NEJM 2023
Semaglutide 7.2 mg: STEP UP; European Commission approval, February 2026
Oral semaglutide 25 mg: OASIS 4; FDA approval December 2025; European Commission approval, July 2026
Orforglipron: ATTAIN-1; FDA approval, April 2026; MHRA authorisation, August 2026
Liraglutide 3.0 mg: SCALE, NEJM 2015
Retatrutide: TRIUMPH-1, Eli Lilly topline results, May 2026
CagriSema: REDEFINE 1, NEJM 2025; FDA filing, December 2025
Amycretin: Phase 1b/2a, The Lancet 2025
Eloralintide: Phase 2, The Lancet 2025
MariTide: Phase 2, NEJM 2025
Survodutide: SYNCHRONIZE-1, NEJM 2026
VK2735: VENTURE and VENTURE-Oral Phase 2 results; VANQUISH program, Viking Therapeutics disclosures, 2025 to 2026
Mazdutide: GLORY-2; NMPA approval, June 2025
Ecnoglutide: NMPA approval, March 2026
NAION and semaglutide: EMA PRAC review, 2025
Comments